Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep 1;23(9):1616-1618.
doi: 10.1093/neuonc/noab125.

Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?

Carmen Balana  1 , Chen Sun  1 , Maria Angeles Vaz  2 , Anna Esteve  3
Affiliations
Comment

Reply to: Extended adjuvant temozolomide in newly diagnosed glioblastoma: the more, the better?

Carmen Balana et al. Neuro Oncol. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(A) Progression-free survival and (B) overall survival for the 134 patients with a wild-type IDH.
See this image and copyright information in PMC

Comment on

References

    1. Balana C, Vaz MA, Manuel Sepúlveda J, et al. . A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). Neuro-Oncology. 2020; 22(12):1851–1861. - PMC - PubMed
    1. Brat DJ, Aldape K, Colman H, et al. . cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139(3):603–608. - PMC - PubMed
    1. Balana C, Carrato C, Vaz MA. Reply to: “extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?” Neuro Oncol. 2020;22(12):1889–1890. - PMC - PubMed
    1. Perry JR, Laperriere N, O’Callaghan CJ, et al. ; Trial Investigators . Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med. 2017;376(11):1027–1037. - PubMed
    1. Blumenthal DT, Gorlia T, Gilbert MR, et al. . Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol. 2017;19(8):1119–1126. - PMC - PubMed